-
1. Blueprint Medicines
Link: https://www.blueprintmedicines.com/
Description: WEBBlueprint Medicines. The urgency of now. We are constantly on the move, relentless in our determination to accelerate development of new therapies, expedite clinical trials and quickly bring approved medicines to patients worldwide. Our pipeline. Photo: C.N., living with systemic mastocytosis.
-
2. Pipeline | Blueprint Medicines
Link: https://www.blueprintmedicines.com/pipeline/
Description: WEBJan 8, 2024 · Selective kinase medicines; Discovery engine; Presentations and publications; Our Blueprint; Pipeline. Overview; Clinical programs; Clinical trials; Early access policy; Investigator sponsored research; Independent medical education; Medicines; Careers. Overview; Life at Blueprint; Meet the Blue Crew; Early Career …
-
3. About | Blueprint Medicines
Link: https://www.blueprintmedicines.com/about/
Description: WEBStriving to improve. human health. We are working to advance a deep pipeline of precision therapies, designed to allow patients to live longer, healthier lives. Our approach combines our leading expertise in protein kinases with sound …
-
4. Medicines | Blueprint Medicines
Link: https://www.blueprintmedicines.com/medicines/
Description: WEBMedicines | Blueprint Medicines. Our medicines. To learn more about AYVAKIT® (avapritinib), visit the product website or download prescribing information below. For patients. Visit AYVAKIT.com. For U.S. healthcare providers. Visit AYVAKIT.com/HCP. U.S. Prescribing Information. Download PDF.
-
5. Science | Blueprint Medicines
Link: https://www.blueprintmedicines.com/science/
Description: WEBWe are a precision therapy company striving to improve human health, developing transformational medicines rooted in our leading expertise.
-
6. Blueprint Medicines' AYVAKYT® (avapritinib) Receives European
Link: https://ir.blueprintmedicines.com/news-releases/news-release-details/blueprint-medicines-ayvakytr-avapritinib-receives-european-0
Description: WEBDec 12, 2023 · Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis. December 12, 2023 at 8:05 AM EST. -- In the European Union, patients with indolent systemic mastocytosis now have an approved medicine that treats the primary driver of …
-
7. Overview | Blueprint Medicines Corp.
Link: https://ir.blueprintmedicines.com/
Description: WEBTransformative science, targeted medicines We are working to advance a deep pipeline of precision therapies, designed to allow patients to live longer, better lives. Our approach combines world-leading expertise in protein kinases with sound execution and an intense focus on discovery.
-
8. Patients | Blueprint Medicines
Link: https://www.blueprintmedicines.com/patients/
Description: WEBAt Blueprint Medicines, we work together in pursuit of one common goal: to dramatically improve the lives of people with genomically defined diseases.
-
9. Our mission and values | Blueprint Medicines
Link: https://www.blueprintmedicines.com/about/our-mission-and-values/
Description: WEBOur mission and values | Blueprint Medicines. Blueprint Medicines aims to make real the promise of precision therapy to improve and extend life for as many people with cancer and hematologic disorders as possible. Our core values.
-
10. Medical professionals | Blueprint Medicines
Link: https://www.blueprintmedicines.com/medical-professionals/
Description: WEBLearn more. U.S. healthcare professionals: Click here for additional scientific information about our approved products and investigational compounds. For more information, contact our medical information department: [email protected].
